Manhattan Research (New York), which has carved out a proprietary space in use of digital media by healthcare providers, released its 2012 Taking the Pulse survey in May; for the first time, the surveying company did all its work online, with no telephone queries, “due to the near ubiquitous online access among US physicians.”
Highlights of the survey are: the meteoric rise of the interactive tablet (primarily, the Apple iPad), now owned or used for professional purposes by 62% of physicians; and a surprising flattening of interest in social media sites for clinical consulting (common among only 7% of physicians), while traditional telephone interactions or face-to-face meetings are the medium of engagement for 81% and 64% of physicians, respectively. Manhattan Research concludes that for social media channels, there is a “low value proposition” and “privacy concerns [are] still a barrier,” according to Monique Levy, VP of research for the company.
Along with the growth of tablet usage, the “three screen” physician is now common: making use of a desktop/laptop; a smartphone; or a tablet. Somewhat surprisingly, one device does not cannibalize another; the more screens physicians use, the more time they spend online.
JOURNALS, COLLEAGUES ARE THE LEADING INFLUENCES ON CLINICAL DECISIONS. credit: Manhattan Research
Information influence
Manhattan Research also polled respondents broadly about their informational influences on clinical decisions (see Figure). As can be expected, peer interactions with colleagues (mostly offline) is the dominant source, both in frequency and in influence. But professional journals (online or offline) are quite high. Pharma reps are strong in reach, but less so in influence. Continuing medical education (CME) and conferences (online and offline) are average influencers, with CME providing more reach.
Within the subset of online learning, Manhattan Research finds that physicians are avid users of online video, especially for CME, online lectures, and disease or condition information. The top destinations for accessing professional videos are WebMD Professional Network, YouTube, QuantiaMD, pharma industry sites, and professional associations.
Taking the Pulse is one part of a comprehensive polling and analytical service from the company; the data are subdivided by physician specialties, and by hardware platforms. Other surveys look at therapeutic segmentations, consumer activities and geographic variations.
Social media sites are stuck on a plateau among physicians
Latest Manhattan Research market study finds little growth in social media usage; also, the rise of the 'three screen' physician
Manhattan Research (New York), which has carved out a proprietary space in use of digital media by healthcare providers, released its 2012 Taking the Pulse survey in May; for the first time, the surveying company did all its work online, with no telephone queries, “due to the near ubiquitous online access among US physicians.”
Highlights of the survey are: the meteoric rise of the interactive tablet (primarily, the Apple iPad), now owned or used for professional purposes by 62% of physicians; and a surprising flattening of interest in social media sites for clinical consulting (common among only 7% of physicians), while traditional telephone interactions or face-to-face meetings are the medium of engagement for 81% and 64% of physicians, respectively. Manhattan Research concludes that for social media channels, there is a “low value proposition” and “privacy concerns [are] still a barrier,” according to Monique Levy, VP of research for the company.
Along with the growth of tablet usage, the “three screen” physician is now common: making use of a desktop/laptop; a smartphone; or a tablet. Somewhat surprisingly, one device does not cannibalize another; the more screens physicians use, the more time they spend online.
JOURNALS, COLLEAGUES ARE THE LEADING INFLUENCES ON CLINICAL DECISIONS. credit: Manhattan Research
Information influence
Manhattan Research also polled respondents broadly about their informational influences on clinical decisions (see Figure). As can be expected, peer interactions with colleagues (mostly offline) is the dominant source, both in frequency and in influence. But professional journals (online or offline) are quite high. Pharma reps are strong in reach, but less so in influence. Continuing medical education (CME) and conferences (online and offline) are average influencers, with CME providing more reach.
Within the subset of online learning, Manhattan Research finds that physicians are avid users of online video, especially for CME, online lectures, and disease or condition information. The top destinations for accessing professional videos are WebMD Professional Network, YouTube, QuantiaMD, pharma industry sites, and professional associations.
Taking the Pulse is one part of a comprehensive polling and analytical service from the company; the data are subdivided by physician specialties, and by hardware platforms. Other surveys look at therapeutic segmentations, consumer activities and geographic variations.
Getting the Lay of the Land After a Banner Year for Biosimilars
March 15th 2024Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.
Almac Group Grows Northern Ireland HQ, Welcomes New Facilities
March 7th 2024The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.
Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
February 20th 2024As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.
ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges
February 19th 2024The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.
Strategizing High-Wire, Multi-Indication Launches
February 14th 2024Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Regeneron Acquires 2seventy bio’s Novel Immune Cell Therapy Pipeline
February 1st 2024Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.
Getting the Lay of the Land After a Banner Year for Biosimilars
March 15th 2024Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.
Almac Group Grows Northern Ireland HQ, Welcomes New Facilities
March 7th 2024The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.
Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
February 20th 2024As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.
ValGenesis, RxCloud Collaborate on Tackling Compliance and Quality Assurance Challenges
February 19th 2024The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.
Strategizing High-Wire, Multi-Indication Launches
February 14th 2024Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Regeneron Acquires 2seventy bio’s Novel Immune Cell Therapy Pipeline
February 1st 2024Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.